Running after ghosts: are dead bacteria the dark matter of the human gut microbiota?


Journal

Gut microbes
ISSN: 1949-0984
Titre abrégé: Gut Microbes
Pays: United States
ID NLM: 101495343

Informations de publication

Date de publication:
Historique:
entrez: 24 3 2021
pubmed: 25 3 2021
medline: 8 1 2022
Statut: ppublish

Résumé

The human gut microbiota has been explored by a wide range of culture-dependent and culture-independent methods, revealing that many microbes remain uncharacterized and uncultured. In this work, we aimed to confirm the hypothesis that some of the species present in the human gut microbiota remain uncultured not because of culture limitations, but because all members of such species are dead before reaching the end of the gastro-intestinal tract.We evaluate this phenomenon by studying the microbial viability and culturability of the human gut microbiota from the fresh fecal materials of eight healthy adults. For the first time, we applied fluorescence-activated cell sorting (FACS) combined with 16S metagenomics analysis and microbial culturomics.We identified a total of 1,020 bacterial OTUs and 495 bacterial isolates through metagenomics and culturomics, respectively. Among the FACS metagenomics results, only 735 bacterial OTUs were alive, comprising on average 42% of known species and 87% of relative abundance per individual. The remaining uncultured bacteria were rare, dead, or injured.Our strategy allowed us to shed light on the dark matter of the human gut microbiota and revealed that both metagenomics and culturomics approaches are needed for greater insight into the diversity and richness of bacteria in the human gut microbiota. Further work on culture is needed to enhance the repertoire of cultured gut bacteria by targeting low abundance bacteria and optimizing anaerobic sample conditioning and processing to preserve the viability of bacteria.

Identifiants

pubmed: 33757378
doi: 10.1080/19490976.2021.1897208
pmc: PMC7993147
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-12

Références

Nat Rev Genet. 2016 Mar;17(3):175-88
pubmed: 26806412
Sci Rep. 2019 Jun 6;9(1):8327
pubmed: 31171823
J Bacteriol. 1937 Apr;33(4):389-400
pubmed: 16560007
EBioMedicine. 2019 Mar;41:509-516
pubmed: 30796005
Microb Ecol. 1982 Dec;8(4):313-23
pubmed: 24226049
Nat Methods. 2013 Dec;10(12):1196-9
pubmed: 24141494
BMC Bioinformatics. 2012 Feb 14;13:31
pubmed: 22333067
Int J Syst Evol Microbiol. 2013 Jul;63(Pt 7):2600-2606
pubmed: 23264499
Appl Environ Microbiol. 2000 Jul;66(7):3044-51
pubmed: 10877804
Nat Rev Genet. 2013 Sep;14(9):618-30
pubmed: 23897237
Cell. 2019 Jan 24;176(3):649-662.e20
pubmed: 30661755
Sci Rep. 2016 May 18;6:26276
pubmed: 27188959
Nat Biotechnol. 2019 Feb;37(2):186-192
pubmed: 30718869
Nat Methods. 2010 May;7(5):335-6
pubmed: 20383131
Front Microbiol. 2019 Jul 10;10:1606
pubmed: 31354688
Nature. 2019 Apr;568(7753):505-510
pubmed: 30867587
Appl Environ Microbiol. 2010 Apr;76(8):2445-50
pubmed: 20173072
Nat Microbiol. 2016 Nov 07;1:16203
pubmed: 27819657
PLoS One. 2019 Oct 21;14(10):e0223543
pubmed: 31634343
BMC Biol. 2009 Nov 03;7:72
pubmed: 19886985
Annu Rev Microbiol. 1985;39:321-46
pubmed: 3904603
Nature. 2016 May 04;533(7604):543-546
pubmed: 27144353
Microbiol Immunol. 2015 Feb;59(2):63-70
pubmed: 25510436
Appl Environ Microbiol. 1999 Nov;65(11):4799-807
pubmed: 10543789
Clin Microbiol Infect. 2012 Dec;18(12):1185-93
pubmed: 23033984
Genome Med. 2016 Jul 01;8(1):72
pubmed: 27363992
Nat Rev Microbiol. 2018 Jun 24;16:540-550
pubmed: 29937540
Bioinformatics. 2010 Oct 1;26(19):2460-1
pubmed: 20709691
Nat Biotechnol. 2019 Feb;37(2):179-185
pubmed: 30718868
PLoS Pathog. 2012;8(5):e1002742
pubmed: 22693451
Proc Natl Acad Sci U S A. 2011 Apr 12;108(15):6252-7
pubmed: 21436049
Genome Biol. 2011 Jun 24;12(6):R60
pubmed: 21702898
Nature. 2019 Apr;568(7753):499-504
pubmed: 30745586
Science. 2005 Jun 10;308(5728):1635-8
pubmed: 15831718
J Mol Biol. 1990 Oct 5;215(3):403-10
pubmed: 2231712
Bioinformatics. 2011 Aug 15;27(16):2194-200
pubmed: 21700674
N Engl J Med. 2016 Dec 15;375(24):2369-2379
pubmed: 27974040

Auteurs

Sara Bellali (S)

IHU Méditerranée Infection, Marseille, France.

Jean-Christophe Lagier (JC)

IHU Méditerranée Infection, Marseille, France.
Aix-Marseille Université, IRD, MEPHI, Marseille, France, Marseille, France.

Matthieu Million (M)

IHU Méditerranée Infection, Marseille, France.
Aix-Marseille Université, IRD, MEPHI, Marseille, France, Marseille, France.

Hussein Anani (H)

IHU Méditerranée Infection, Marseille, France.

Gabriel Haddad (G)

IHU Méditerranée Infection, Marseille, France.
Aix-Marseille Université, IRD, MEPHI, Marseille, France, Marseille, France.

Rania Francis (R)

IHU Méditerranée Infection, Marseille, France.
Aix-Marseille Université, IRD, MEPHI, Marseille, France, Marseille, France.

Edmond Kuete Yimagou (E)

IHU Méditerranée Infection, Marseille, France.

Saber Khelaifia (S)

IHU Méditerranée Infection, Marseille, France.

Anthony Levasseur (A)

IHU Méditerranée Infection, Marseille, France.
Aix-Marseille Université, IRD, MEPHI, Marseille, France, Marseille, France.

Didier Raoult (D)

IHU Méditerranée Infection, Marseille, France.

Jacques Bou Khalil (J)

IHU Méditerranée Infection, Marseille, France.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH